Stockreport

ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF If approved, Daiichi Sankyo and AstraZeneca's ENHERTU has the potential to become a new standard of care in this early breast cancer setting TOKYO & BASKING RIDGE, N. [Read more]